CPT Codes Mapped to CVX Codes

This table cross-references Current Procedural Terminology (CPT^TM) codes that are related to vaccines, toxoids and immune globulins with their corresponding CVX codes. The goal of the table is to support mapping of CPT codes to CVX codes in systems that receive CPT codes as part of an electronic data exchange. The CVX and/or NDC code systems are highly recommended when exchanging immunization data, but if a sending system must use CPT codes, this table may be used by the receiving system to translate the CPT code to the single best CVX code equivalent. In all cases, the code utilized, be it NDC, CVX or CPT, should be the most specific and granular representation possible of the vaccine given. Where only a single vaccine exists, the CPT code is mapped to that vaccine specific CVX code. However, in many cases, a single CPT code could be used with multiple vaccines utilizing different CVX codes. In this situation, the CPT code is mapped to the "unspecified formulation" CVX code because it is not possible to infer a specific vaccine formulation from the CPT code alone.
This table is not intended to support mapping from CVX to CPT nor to be a definitive source for CPT codes. Practices must approach billing for vaccines (selection of a CPT code for a given administration) independently from recording and reporting the most specific vaccine codes to an IIS or other clinical trading partner. Active CPT codes, inactive CPT codes and pre-release CPT codes are included. Every effort is made to keep the codes current.

Available Printable versions: Excel     Pdf     Flat File    XML format

Sort Table by Column: Simply click on the column heading to sort the table accordingly.

The Last Updated column indicates the last time this particular CPT code was updated in this table.

CPT CODE	CPT Description	CVX Code	Vaccine Name	Comments	Last Updated Date
90281	Immune globulin (Ig), human, for intramuscular use	86	IG		6/13/2024
90283	Immune globulin (IgIV), human, for intravenous use	87	IGIV		6/13/2024
90287	Botulinum antitoxin, equine, any route	27	botulinum antitoxin		6/13/2024
90291	Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use	29	CMVIG		6/13/2024
90296	Diphtheria antitoxin, equine, any route	12	diphtheria antitoxin		6/13/2024
90371	Hepatitis B immune globulin (HBIg), human, for intramuscular use	30	HBIG		6/13/2024
90375	Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use	34	RIG		6/13/2024
90376	Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use	34	RIG		6/13/2024
90378	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each	93	RSV-MAb		6/13/2024
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	306	RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months	CPT Code to be used for Beyfortus 0.5 mL	6/13/2024
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	307	RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months	CPT Code to be used for Beyfortus 1.0 mL	6/13/2024
90382	Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use	332	RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF		6/26/2025
90389	Tetanus immune globulin (TIg), human, for intramuscular use	13	TIG		6/13/2024
90393	Vaccinia immune globulin, human, for intramuscular use	79	vaccinia immune globulin		6/13/2024
90396	Varicella-zoster immune globulin, human, for intramuscular use	36	VZIG		6/13/2024
90470	H1N1 immunization administration (intramuscular, intranasal), including counseling when performed	128	Novel Influenza-H1N1-09, all formulations		2/28/2017
90476	Adenovirus vaccine, type 4, live, for oral use	54	adenovirus, type 4		6/13/2024
90477	Adenovirus vaccine, type 7, live, for oral use	55	adenovirus, type 7		6/13/2024
90581	Anthrax vaccine, for subcutaneous or intramuscular use	318	Anthrax, post-exposure prophylaxis		6/13/2024
90581	Anthrax vaccine, for subcutaneous or intramuscular use	24	Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis		6/13/2024
90585	Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use	19	BCG		6/13/2024
90587	Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use	56	dengue fever tetravalent		6/13/2024
90589	Chikungunya virus vaccine, live attenuated, for intramuscular use	317	Chikungunya live attenuated vaccine, 0.5 mL, PF		6/13/2024
90593	Chikungunya virus vaccine, recombinant, for intramuscular use	329	Chikungunya, VLP, recombinant, 0.8 mL, PF		4/15/2025
90611	Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use	206	Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection	CPT Code to be used for JYNNEOS vaccine	6/13/2024
90619	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use	203	meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)		6/13/2024
90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), for intramuscular use	163	meningococcal B, OMV		4/15/2025
90621	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use	162	meningococcal B, recombinant		6/13/2024
90622	Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use	75	Vaccinia (smallpox, monkeypox), live	CPT Code to be used for ACAM2000 vaccine	6/13/2024
90623	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use	316	Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF		6/13/2024
90624	Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use	328	Meningococcal oligosaccharide (MenACWY), (MenB), PF		7/9/2024
90625	Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use	174	cholera, live attenuated		6/13/2024
90626	Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use	223	Tick-borne encephalitis, inactivated, PF, 0.25mL		6/13/2024
90627	Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use	224	Tick-borne encephalitis, inactivated, PF, 0.5mL		6/13/2024
90630	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use	166	influenza, intradermal, quadrivalent, preservative free		9/24/2024
90632	Hepatitis A vaccine (HepA), adult dosage, for intramuscular use	52	Hep A, adult		6/13/2024
90633	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use	83	Hep A, ped/adol, 2 dose		6/13/2024
90634	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use	84	Hep A, ped/adol, 3 dose		6/13/2024
90636	Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use	104	Hep A-Hep B		6/13/2024
90644	Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use	148	Meningococcal C/Y-HIB PRP		6/13/2024
90645	Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use	47	Hib (HbOC)		2/28/2017
90646	Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use	46	Hib (PRP-D)		2/28/2017
90647	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	49	Hib (PRP-OMP)		6/13/2024
90648	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use	48	Hib (PRP-T)		6/13/2024
90649	Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use	62	HPV, quadrivalent		6/13/2024
90650	Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use	118	HPV, bivalent		6/13/2024
90651	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	165	HPV9		6/13/2024
90653	Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use	168	Influenza, adjuvanted, trivalent, PF		6/13/2024
90654	Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use	144	influenza, seasonal, intradermal, preservative free		9/24/2024
90656	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use	140	Influenza, split virus, trivalent, PF		6/13/2024
90657	Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use	141	Influenza, split virus, trivalent, preservative		6/13/2024
90658	Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use	141	Influenza, split virus, trivalent, preservative		6/13/2024
90659	Influenza virus vaccine, whole virus, for intramuscular or jet injection use	16	influenza, whole		2/28/2017
90660	Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use	111	Influenza, live, trivalent, intranasal, PF		6/13/2024
90661	Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use	320	Influenza, MDCK, trivalent, preservative		9/24/2024
90661	Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use	153	Influenza, MDCK, trivalent, PF		9/24/2024
90662	Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	197	Influenza, high-dose, quadrivalent, PF		6/13/2024
90662	Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	135	Influenza, high-dose, trivalent, PF		6/13/2024
90663	Influenza virus vaccine, pandemic formulation, H1N1	128	Novel Influenza-H1N1-09, all formulations		2/28/2017
90664	Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use	125	Novel Influenza-H1N1-09, nasal		6/13/2024
90665	Lyme disease vaccine, adult dosage, for intramuscular use	66	Lyme disease		2/28/2017
90666	Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use	126	Novel influenza-H1N1-09, preservative-free		6/13/2024
90668	Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use	127	Novel influenza-H1N1-09		6/13/2024
90669	Pneumococcal conjugate vaccine, 7 valent, for intramuscular use	100	pneumococcal conjugate PCV 7		2/28/2017
90670	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	133	Pneumococcal conjugate PCV 13		6/13/2024
90671	Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use	215	Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF		6/13/2024
90672	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	149	Influenza, live, quadrivalent, intranasal		6/13/2024
90673	Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	155	Influenza, recombinant, trivalent, PF		6/13/2024
90674	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	171	Influenza, MDCK, quadrivalent, PF		6/13/2024
90675	Rabies vaccine, for intramuscular use	176	Rabies - IM fibroblast culture		6/13/2024
90675	Rabies vaccine, for intramuscular use	175	Rabies - IM Diploid cell culture		6/13/2024
90676	Rabies vaccine, for intradermal use	40	rabies, intradermal injection		6/13/2024
90677	Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use	216	Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF		6/13/2024
90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	305	RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF	CPT Code to be used for ABRYSVO	6/13/2024
90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use	303	RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF	CPT Code to be Used for Arexvy	6/13/2024
90680	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	116	rotavirus, pentavalent		6/13/2024
90681	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	119	rotavirus, monovalent		6/13/2024
90682	Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	185	Influenza, recombinant, quadrivalent, PF		6/13/2024
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	326	RSV, mRNA, injectable, PF		6/13/2024
90684	Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use	327	Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF		7/9/2024
90685	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use	161	Influenza, injectable,quadrivalent, preservative free, pediatric		6/13/2024
90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	150	Influenza, split virus, quadrivalent, PF		6/13/2024
90687	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use	158	Influenza, split virus, quadrivalent, preservative		6/13/2024
90688	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	158	Influenza, split virus, quadrivalent, preservative		6/13/2024
90690	Typhoid vaccine, live, oral	25	typhoid, oral		6/13/2024
90691	Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use	101	typhoid, ViCPs		6/13/2024
90692	Typhoid vaccine, heat- and phenol-inactivated (H-P), for subcutaneous or intradermal use	41	typhoid, parenteral		2/28/2017
90693	Typhoid vaccine, acetone-killed, dried (AKD), for subcutaneous use (U.S. military)	53	typhoid, parenteral, AKD (U.S. military)		2/28/2017
90694	Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use	205	Influenza, adjuvanted, quadrivalent, PF		6/13/2024
90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	130	DTaP-IPV		6/13/2024
90697	Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use	146	DTaP,IPV,Hib,HepB		6/13/2024
90698	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	120	DTaP-Hib-IPV		6/13/2024
90700	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use	20	DTaP		6/13/2024
90700	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use	106	DTaP, 5 pertussis antigens		6/13/2024
90701	Diphtheria, tetanus toxoids, and whole cell pertussis vaccine (DTP), for intramuscular use	01	DTP		2/28/2017
90702	Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use	28	DT (pediatric)		6/13/2024
90703	Tetanus toxoid adsorbed, for intramuscular use	35	tetanus toxoid, adsorbed		2/28/2017
90704	Mumps virus vaccine, live, for subcutaneous use	07	mumps		2/28/2017
90705	Measles virus vaccine, live, for subcutaneous use	05	measles		2/28/2017
90706	Rubella virus vaccine, live, for subcutaneous use	06	rubella		2/28/2017
90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	03	MMR		6/13/2024
90708	Measles and rubella virus vaccine, live, for subcutaneous use	04	M/R		2/28/2017
90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	94	MMRV		6/13/2024
90712	Poliovirus vaccine, (any type[s]) (OPV), live, for oral use	182	OPV, Unspecified		2/28/2017
90713	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	10	IPV		6/13/2024
90714	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	113	Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed	Beginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code.	6/13/2024
90714	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	09	Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed	Beginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code.	6/13/2024
90715	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use	115	Tdap		6/13/2024
90716	Varicella virus vaccine (VAR), live, for subcutaneous use	21	varicella		6/13/2024
90717	Yellow fever vaccine, live, for subcutaneous use	183	Yellow fever vaccine live - alt		6/13/2024
90717	Yellow fever vaccine, live, for subcutaneous use	37	yellow fever live		6/13/2024
90720	Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use	22	DTP-Hib		2/28/2017
90721	Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DTaP/Hib), for intramuscular use	50	DTaP-Hib		2/28/2017
90723	Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use	110	DTaP-Hep B-IPV		6/13/2024
90724	Influenza virus vaccine	88	influenza, unspecified formulation		3/3/2017
90725	Cholera vaccine for injectable use	26	cholera, unspecified formulation		2/28/2017
90726	Rabies vaccine	90	rabies, unspecified formulation		3/3/2017
90727	Plague vaccine, for intramuscular use	23	plague		2/28/2017
90728	BCG vaccine	19	BCG		3/3/2017
90730	Hepatitis A vaccine	85	Hep A, unspecified formulation		3/3/2017
90731	Hepatitis B vaccine	45	Hep B, unspecified formulation		3/3/2017
90732	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use	33	pneumococcal polysaccharide PPV23		6/13/2024
90733	Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use	32	meningococcal MPSV4		6/13/2024
90734	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use	136	Meningococcal MCV4O		6/13/2024
90734	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use	114	meningococcal MCV4P		6/13/2024
90735	Japanese encephalitis virus vaccine, for subcutaneous use	39	Japanese encephalitis SC		2/28/2017
90736	Zoster (shingles) vaccine (HZV), live, for subcutaneous injection	121	zoster live		6/13/2024
90737	Hemophilus influenza B	17	Hib, unspecified formulation		3/3/2017
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use	134	Japanese Encephalitis IM		6/13/2024
90739	Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use	189	HepB-CpG		6/13/2024
90740	Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use	44	Hep B, high-dosage, dialysis or IC		6/13/2024
90741	Immunization, passive; immune serum globulin, human (ISG)	14	IG, unspecified formulation		3/3/2017
90743	Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use	43	Hep B, adult		6/13/2024
90743	Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use	08	Hep B, adolescent or pediatric		6/13/2024
90744	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	08	Hep B, adolescent or pediatric		6/13/2024
90745	Hepatitis B vaccine, adolescent/high risk infant dosage, for intramuscular use	42	Hep B, adolescent/high risk infant		3/3/2017
90746	Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use	43	Hep B, adult		6/13/2024
90747	Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use	44	Hep B, high-dosage, dialysis or IC		12/11/2024
90748	Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use	51	Hib-Hep B		6/13/2024
90750	Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use	187	zoster recombinant		6/13/2024
90756	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use	186	Influenza, MDCK, quadrivalent, preservative	Effective 1/1/2018	6/13/2024
90758	Zaire ebolavirus vaccine, live, for intramuscular use	204	Ebola Zaire vaccine, live, recombinant, 1mL dose		6/13/2024
90759	Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use	220	HepB recombinant, 3-antigen, Al(OH)3		6/13/2024
91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	208	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose	COVID-19 Vaccine - EUA authorized 12/11/2020	6/13/2024
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	207	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	COVID-19 Vaccine - BLA Licensed and EUA authorized	6/13/2024
91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use	210	COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL	COVID-19 Vaccine - EUA submission withdrawn	6/13/2024
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use	212	COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL	COVID-19 Vaccine - EUA authorized 2/27/2021	6/13/2024
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use	313	COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL	Original and Fall COVID-19 vaccine starting 2023	9/24/2024
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use	211	COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL	Original and Fall COVID-19 vaccine starting 2023	9/24/2024
91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	217	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	COVID-19 Vaccine - EUA authorized for primary series and IC, EUA rescinded 8/31/202 for monovalent boosters	6/13/2024
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	207	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	COVID-19 Vaccine - EUA authorization rescinded 8/31/2022 for adult monovalent booster dose	6/13/2024
91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	218	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	COVID-19 Vaccine - EUA authorized, pediatric 5 yrs through 11 yrs dose requires dilution	6/13/2024
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	219	COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose	COVID-19 Vaccine - EUA authorized for children under 5 yrs	6/13/2024
91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	221	COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose	COVID-19 Vaccine - EUA authorized for pediatric, EUA rescinded 8/31/2022 for adult monovalent booster dose	6/13/2024
91310	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use	225	COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL	COVID-19 Vaccine - Potential EUA authorization booster dose	6/13/2024
91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	228	COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose	COVID-19 Vaccine - EUA authorized for ages 6 mo through 5 yrs	6/13/2024
91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	300	COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose	COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster ages 12+ yrs	6/13/2024
91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	229	COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose	COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 18+ yrs, potential EUA ages 6 yrs through 17 yrs	6/13/2024
91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	229	COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose	COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 6 yrs through 11 yrs	6/13/2024
91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	301	COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose	COVID-19 Vaccine - Potential EUA authorization bivalent booster for ages 5 yrs through 11 yrs	6/13/2024
91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use	230	COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL	COVID-19 Vaccine - EUA authorized 12/8/2022 bivalent booster (Moderna) for ages 6 mo through 5 yrs	6/13/2024
91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	302	COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose	COVID-19 Vaccine - EUA authorized 12/8/2022 bivalent vaccine (Pfizer) for ages 6 mo through 4 yrs	6/13/2024
91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	308	COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL	Fall COVID-19 vaccine starting 2023	9/24/2024
91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	310	COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL	Fall COVID-19 vaccine starting 2023	9/24/2024
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	309	COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL	Fall COVID-19 vaccine starting 2023	9/24/2024
91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	311	COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL	Fall COVID-19 vaccine starting 2023	9/24/2024
91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	312	COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL	Fall COVID-19 vaccine starting 2023	9/24/2024
91323	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use	334	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL		4/15/2025

 Top of Page

---

CPT codes are developed and maintained by the American Medical Association (AMA) and are intended to support billing for services. CPT codes have been reproduced here with permission from the AMA. CPT five-digit codes, nomenclature and other data are Copyright, American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in this cross-reference. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.

CVX codes are codes that indicate the product used in a vaccination. They are maintained by the Centers for Disease Control and Prevention, Immunization Information System Support Branch (IISSB) for use in HL7 data transmission.

Questions regarding this table should be directed to the IIS Technical Assistance Team; CDC, National Centers for Immunization and Respiratory Diseases, Immunization Information Systems Support Branch-Informatics, 1600 Clifton Road, Mailstop E-62, Atlanta, GA 30333.

For further information on HL7 immunization data exchange and the CVX code set, contact the IIS Technical Assistance Team at:

Address:

CDC, National Centers for Immunization and Respiratory Diseases
Immunization Information System Support Branch - Informatics
1600 Clifton Road
Mailstop: E-62
Atlanta, GA 30333

Email:

iisinfo@cdc.gov (note change)

Related Pages

• IIS: HL7 Standard Code Set MVX - Manufacturers of Vaccines
• IIS: HL7 Standard Code Set CVX - Vaccines Administered